Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

Trial Profile

Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs MEDI 570 (Primary)
  • Indications Cutaneous T cell lymphoma; Follicular lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 14 Apr 2016 Planned primary completion date changed from 1 Nov 2017 to 1 May 2018.
    • 12 Apr 2016 Planned initiation date changed from 1 Nov 2015 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top